Thermo Fisher Scientific Inc. $TMO Shares Acquired by Professional Advisory Services Inc.

Professional Advisory Services Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,819 shares of the medical research company’s stock after buying an additional 5,804 shares during the quarter. Thermo Fisher Scientific comprises 3.9% of Professional Advisory Services Inc.’s portfolio, making the stock its 5th biggest holding. Professional Advisory Services Inc.’s holdings in Thermo Fisher Scientific were worth $32,498,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Howard Capital Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock worth $1,791,000 after acquiring an additional 16 shares during the last quarter. Salomon & Ludwin LLC boosted its position in Thermo Fisher Scientific by 1.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock valued at $669,000 after buying an additional 17 shares during the period. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its holdings in Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after acquiring an additional 20 shares during the period. Finally, Elyxium Wealth LLC lifted its position in Thermo Fisher Scientific by 1.9% in the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $593.11 on Friday. The company has a 50-day simple moving average of $517.63 and a two-hundred day simple moving average of $510.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market capitalization of $219.30 billion, a PE ratio of 31.90, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Insider Buying and Selling

In related news, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $8,574,720. This trade represents a 28.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,250 shares of company stock worth $12,235,950 in the last three months. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on TMO shares. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Stifel Nicolaus set a $650.00 target price on Thermo Fisher Scientific in a research note on Wednesday. Finally, Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.